

References

1. **Akinsegun Akinbam , Adedoyin Dosunmu, Adewumi Adediran, Olajumoke Oshinaike, Phillip Adebola and Olanrewaju Arogundade, (2012)**, Hematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria ; BMC Research Notes, 5:396
2. **Ariel Katz; Chioma A. Ekeh; Magdalena A. Danch; Emad U. Hakemi; German E. Giese; Franklin Njoku; Maryam Sanati; Brian P. Lucas, (2012)** Use of reticulocyte production index in anemic inpatients, Stroger Hospital of Cook County, Chicago, IL; Rush University, Chicago, IL. JGIM op 1: p344.
3. **Ballas SK, Et Al. (2010)** Definitions Of The Phenotypic Manifestations Of Sickle Cell Disease. Am J Hematol;85:6-13.
4. **Chinegwundoh F, Anie KA.** Treatments for priapism in boys and men with sickle cell disease (Review) reprint. Cochrane Database of Systematic Reviews 2009.
5. **Craft S, Schatz J, Glauser TA, Lee B, DeBaun MR.** Neuropsychologic effects of stroke in children with sickle cell anemia. J Pediatr 1993;123:712-7.
6. **Daak AA, Ghebremeskel K, Hassan Z, Attallah B, Azan HH, Elbashir MI, Crawford M. (2013)** ,Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. Jan;97(1):37-44.
7. **Dyerberg J, Bang HO, Hjerne N (1975).** "Fatty acid composition of the plasma lipids in Greenland Eskimos". Am J Clin Nutr 28 (9): 958-66. PMID 1163480

8. **Frenette PS, Atweh GF. Sickle Cell Disease(2007):** Old Discoveries, New Concepts, And Future Promise. J Clin Invest;117:850-8.
9. **Gladwin MT, Sachdev V, Jison ML, et al.(2004)** Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med;350:886-95.
10. **Akinsegun Akinbami, Addoyin Dosunmu, Adewumi Adediran, Olajumoke Oshinaike, Phillip Adebola and Olanrewaju Arogundade,** Haematological values in sickle cell anaemia in steady state and during vaso-occlusive crisis in benin city, nigeria Annals Of African Medicine Vol. 4, No. 2; 2005: 62 - 67
11. **Hogan AM,Et Al(2006).** Physiological Correlates Of Intellectual Function In Children With Sickle Cell Disease: Hypoxaemia, Hyperaemia And Brain Infarction. Dev Sci; 9:379-87.
12. **Hoffbrand Av, PAH Moss And IE Pettit(2005)** Essential Haematology, 5th Edition , Blackwell Publishing Ltd, ;85-93
13. **Kaul DK, Fabry ME, Nagel RL(1996).** The Pathophysiology Of Vascular Obstruction In The Sickle Syndromes. Blood Rev;10:29-44.
14. **Kirkham FJ. (2007)** Therapy Insight: Stroke Risk And Its Management In Patients With Sickle Cell Disease. Nat Clin Pract Neurol;3:264-78.
15. **Maton, Anthea; Jean Hopkins, Charles William McLaughlin, Susan Johnson, Maryanna Quon Warner, David LaHart, Jill D. Wright (1993).** *Human Biology and Health.* Englewood Cliffs, New Jersey, USA: Prentice Hall. ISBN 0-13-981176-1.

16. **Mayer K,(2002)**, Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. *Am J Physiol Heart Circ Physiol*;283:H811-8.
17. **McKie KT, Hanevold CD, Hernandez C, Waller JL, Ortiz L, McKie KM. (2007)**, Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease. *J Pediatr Hematol Oncol*;29:140-4.
18. **National Heart, Lung, And Blood Institute. (2008)**, Sickle Cell Anemia. Diseases And Conditions Index. Retrieved at march 2013 From [Http://Www.Nhlbi.Nih.Gov/Health/Dci/Diseases/Sca/SCA_Whoisatrisk.H tml](http://www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_Whoisatrisk.html),
19. **Okpala I. (2006)**, Leukocyte Adhesion And The Pathophysiology Of Sickle Cell Disease. *Curr Opin Hematol*;13:40-4.
20. **Omoti C. E. (2005)** haematological values in sickle cell anaemia in steady state and during vaso-occlusive crisis in benin city, nigeria *annals of african medicine* vol. 4, no. 2;: 62 - 67
21. **Platt OS, Brambilla DJ, Rosse WF, et al. (1994)**, Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med*;330:1639-44.
22. **Rees DC, Williams TN, Gladwin MT. (2010)**, Sickle-Cell Disease. *Lancet*;376:2018-31.
23. **Ren H, Obike I, Okpala I, Ghebremeskel K, Ugochukwu C, Crawford M. (2005)**, Steady-state haemoglobin level in sickle cell anaemia increases with an increase in erythrocyte membrane n23 fatty acids. *Prostaglandins Leukot Essent Fatty Acids*;72:415-21.

24. **Ruxton CH, et al, (2005)**, The impact of long-chain n–3 polyunsaturated fatty acids on human health. *Nutr Res Rev*;18:113–29
25. **Serjeant GR, Serjeant BE. (2001)**, *Sickle Cell Disease*. 3rd Ed. Oxford, United Kingdom: Oxford University Press,.
26. **Tomer A, Kasey S, Connor WE, et al. (2001)** Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. *Thromb Haemost.*;85:966-974.
27. US National Library Of Medicine National Institutes Of Health 2011 Jul;119(7):442-8.
28. **Vichinsky EP, Neumayr LD, Earles AN, et al. (2000)**, Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study group. *N Engl J Med*;342:1855-65.
29. **Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. (1997)**, Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. *Blood*;89:1787-92
30. **Weatherall DJ, Akinyanju O, Fucharoen S, Olivieri NF, Musgrove P. (2006)**, *Inherited Disorders Of Hemoglobin* In: Jamison DT, Bobadilla JS, Mosley WH, Measham AR. *Disease Control Priorities In Developing Countries*. New York, NY: Oxford University Press And The World Bank,:663–80
31. **Williams TN, Uyoga S, Macharia A, et al. (2009)**; Bacteraemia in Kenyan children with sickle-cellanaemia: a retrospective cohort and case-control study. *Lancet* 374:1364-70.